Elena Anghileri

Medicine & Life Sciences

1. Glioblastoma 100%
2. Glioma 69%
3. alpha-hydroxyglutarate 57%
4. Fluorescein 51%
5. Temozolomide 47%
6. Survival 33%
7. Mesenchymal Stem Cells 32%
8. Dendritic Cells 32%
9. Medulloblastoma 29%
10. Irinotecan 28%
11. Bevacizumab 28%
12. Drug Therapy 27%
13. Neoplasms 27%
14. Natural Killer Cells 23%
15. Autoantigens 23%
16. Autoimmune Experimental Encephalomyelitis 23%
17. Multiple Sclerosis 23%
18. Acute Hemorrhagic Leukoencephalitis 21%
19. 2-Hydroxyglutaricaciduria 21%
20. Immunotherapy 21%
21. Multicenter Studies 20%
22. Observational Studies 20%
23. Central Nervous System 19%
24. Magnetic Resonance Spectroscopy 18%
25. Catheters 18%
26. Immunoglobulin G 18%
27. Brain 17%
28. Prospective Studies 17%
29. Hashimoto's encephalitis 17%
30. Neuroepithelial Neoplasms 17%
31. Sumatriptan 16%
32. Brain Neoplasms 16%
33. Cluster Headache 16%
34. Retrospective Studies 16%
35. Fatty Acid-Binding Proteins 15%
36. Leptin Receptors 15%
37. Autoantibodies 15%
38. Neoplasm Metastasis 15%
39. Progression-Free Survival 14%
40. Neurofibromatosis 1 14%
41. Cyclin-Dependent Kinases 14%
42. Proton Magnetic Resonance Spectroscopy 14%
43. Vertigo 13%
44. Meningioma 13%
45. Cerebral Blood Volume 12%
46. Neurology 12%
47. Dizziness 12%
48. Oligonucleotide Array Sequence Analysis 12%
49. Karnofsky Performance Status 12%
50. Microarray Analysis 12%